Here, we have selected EphA2 as a target for proof‐of‐concept purposes; however, identifying more selective markers that are minimally expressed in normal paediatric tissues remains an active area of investigation to enhance the safety of CAR‐NK cell therapies for sarcoma. The gene discussed is EPHA2; the disease is sarcoma.